title: Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management.
abstract: New-onset diabetes after transplantation (NODAT) is major complication following renal transplantation. It commonly develops within 3-6 mo post-transplantation. The development of NODAT is associated with significant increase in risk of major cardiovascular events and cardiovascular death. Other dysglycemic states, such as impaired glucose tolerance are also associated with increasing risk of cardiovascular events. The pathogenesis of these dysglycemic states is complex. Older recipient age is a consistent major risk factor and the impact of calcineurin inhibitors and glucocorticoids has been well described. Glucocorticoids likely cause insulin resistance and calcineurin inhibitors likely cause β-cell toxicity. The impact of transplantation in incretin hormones remains to be clarified. The oral glucose tolerance test remains the best diagnostic test but other tests may be validated as screening tests. Possibly, NODAT can be prevented by administering insulin early in patients identified as high risk for NODAT. Once NODAT has been diagnosed altering immunosuppression may be acceptable, but creates the difficulty of balancing immunological with metabolic risk. With regard to hypoglycemic use, metformin may be the best option. Further research is needed to better understand the pathogenesis, identify high risk patients and to improve management options given the significant increased risk of major cardiovascular events and death.
authors: David Langsford, Karen Dwyer, Department of Nephrology, St Vincent's Hospital Melbourne, Fitzroy 3065, Australia.
authors: David
authors: D
authors: Langsford
authors: David Langsford, Karen Dwyer, Department of Nephrology, St Vincent's Hospital Melbourne, Fitzroy 3065, Australia.
authors: Karen
authors: K
authors: Dwyer
keywords: Diabetes; Epidemiology; Management; Pathogenesis; Renal transplantation